| Name | Title | Contact Details |
|---|
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").
Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.
Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.
Spine Vision is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.